Neurocrine biosciences earnings. The transaction is subject to customary closing conditions and is expected to close in late January 2026. At Neurocrine Biosciences, our purpose is simple: to relieve suffering for people with great needs, but few options. Dec 16, 2024 · After seven decades with no advances in the treatment of congenital adrenal hyperplasia, Neurocrine has scored an FDA approval for Crenessity. You Deserve Brave Science | Neurocrine Biosciences is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. . In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD). Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. Science is in our DNA—our founders were scientists, and their drive to discover is still felt as we continue to investigate potential treatments for rare diseases and conditions. Our dedication to discovery remains unwavering after more than 30 years of investigating potential life-changing treatments for patients with neurological, neuroendocrine, and neuropsychiatric disorders. Jul 1, 2024 · Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. aef bknwr lgiefb jinxh ftgnt xgr lfbvpz wdorl ohebd rei